NBIX
$135.42
Revenue | $622.1Mn |
Net Profits | $129.8Mn |
Net Profit Margins | 20.86% |
Neurocrine Biosciences Inc.’s revenue jumped 24.72% since last year same period to $622.1Mn in the Q3 2024. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 5.4% jump in its revenue since last 3-months.
Neurocrine Biosciences Inc.’s net profit jumped 56.2% since last year same period to $129.8Mn in the Q3 2024. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 99.69% jump in its net profits since last 3-months.
Neurocrine Biosciences Inc.’s net profit margin jumped 25.24% since last year same period to 20.86% in the Q3 2024. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated 89.45% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | 1.51 |
EPS Estimate Current Year | 1.51 |
Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.51 - a 43.81% jump from last quarter’s estimates.
Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current year stand at 1.51.
Earning Per Share (EPS) | 1.24 |
Neurocrine Biosciences Inc.’s earning per share (EPS) jumped 51.22% since last year same period to 1.24 in the Q3 2024. This indicates that the Neurocrine Biosciences Inc. has generated 51.22% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2024-05-01 | 1.01 | 0.42 | -58.42% |
2024-10-30 | 1.51 | 1.24 | -17.88% |
2024-08-01 | 1.05 | 0.63 | -40% |